| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
159,210,000 |
| Market
Cap: |
1.08(B) |
| Last
Volume: |
2,204,422 |
Avg
Vol: |
2,198,299 |
| 52
Week Range: |
$1.78 - $6.34 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company engaging in developing, manufacturing, marketing and distributing generic and branded pharmaceutical products across an array of dosage forms and therapeutic areas. Co. has three reportable segments: Generics, which includes various product families covering a range of dosage forms and delivery systems; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders; and AvKARE, which provides pharmaceuticals, medical and surgical products, and services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Reasons Bryan M. |
Chief Financial Officer |
• • – |
2016-02-26 |
4 |
D |
$33.27 |
$65,143 |
D/D |
(1,958) |
66,732 |
|
- |
|
| Wilkinson George Fred |
Chief Executive Officer |
• • – |
2016-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
89,332 |
526,456 |
|
- |
|
| Wilkinson George Fred |
Chief Executive Officer |
• • – |
2016-02-26 |
4 |
D |
$33.27 |
$185,214 |
D/D |
(5,567) |
437,124 |
|
- |
|
| Wilkinson George Fred |
Chief Executive Officer |
• • – |
2015-10-29 |
4 |
D |
$35.75 |
$587,194 |
D/D |
(16,425) |
442,691 |
|
- |
|
| Nornhold Jeffrey |
SVP, Technical Operations |
• • – |
2015-10-28 |
4 |
D |
$36.94 |
$46,951 |
D/D |
(1,271) |
64,200 |
|
- |
|
| Nornhold Jeffrey |
SVP, Technical Operations |
• • – |
2015-10-26 |
4 |
D |
$35.97 |
$84,494 |
D/D |
(2,349) |
65,471 |
|
- |
|
| Reasons Bryan M. |
Chief Financial Officer |
• • – |
2015-10-26 |
4 |
D |
$35.97 |
$46,725 |
D/D |
(1,299) |
68,690 |
|
- |
|
| Nornhold Jeffrey |
SVP, Technical Operations |
• • – |
2015-10-25 |
4 |
D |
$35.63 |
$90,429 |
D/D |
(2,538) |
67,820 |
|
- |
|
| Vergis Janet S. |
Director |
• • – |
2015-10-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
3,400 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• • – |
2015-09-11 |
4 |
S |
$43.30 |
$322,888 |
D/D |
(7,457) |
73,588 |
|
- |
|
| Benet Leslie Z |
Director |
• • – |
2015-09-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
12,350 |
|
- |
|
| Nestor Michael |
President, Impax Pharm. |
• • – |
2015-09-10 |
4 |
S |
$43.56 |
$217,800 |
D/D |
(5,000) |
111,833 |
|
- |
|
| Benet Leslie Z |
Director |
• • – |
2015-09-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
850 |
15,350 |
|
- |
|
| Benet Leslie Z |
Director |
• • – |
2015-09-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
16,200 |
|
- |
|
| Benet Leslie Z |
Director |
• • – |
2015-09-01 |
4 |
OE |
$6.55 |
$58,950 |
D/D |
9,000 |
18,200 |
|
- |
|
| Benet Leslie Z |
Director |
• • – |
2015-08-31 |
4 |
S |
$40.92 |
$818,400 |
D/D |
(20,000) |
9,200 |
|
- |
|
| Benet Leslie Z |
Director |
• • – |
2015-08-31 |
4 |
OE |
$6.55 |
$434,678 |
D/D |
20,000 |
11,700 |
|
- |
|
| Fleming Nigel |
Director |
• • – |
2015-08-31 |
4 |
S |
$41.02 |
$1,196,389 |
D/D |
(29,166) |
8,200 |
|
- |
|
| Fleming Nigel |
Director |
• • – |
2015-08-31 |
4 |
OE |
$17.99 |
$451,420 |
D/D |
23,000 |
13,200 |
|
- |
|
| Markbreiter Michael |
Director |
• • – |
2015-08-31 |
4 |
S |
$41.39 |
$827,800 |
D/D |
(20,000) |
8,200 |
|
- |
|
| Markbreiter Michael |
Director |
• • – |
2015-08-31 |
4 |
OE |
$20.30 |
$412,000 |
D/D |
20,000 |
18,200 |
|
- |
|
| Markbreiter Michael |
Director |
• • – |
2015-08-28 |
4 |
S |
$42.48 |
$339,840 |
D/D |
(8,000) |
8,200 |
|
- |
|
| Markbreiter Michael |
Director |
• • – |
2015-08-28 |
4 |
OE |
$17.99 |
$143,920 |
D/D |
8,000 |
16,200 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• • – |
2015-08-27 |
4 |
S |
$43.41 |
$201,813 |
D/D |
(4,649) |
81,045 |
|
- |
|
| Terreri Peter R |
Director |
• • – |
2015-08-27 |
4 |
S |
$43.93 |
$212,314 |
D/D |
(4,833) |
39,787 |
|
- |
|
215 Records found
|
|
Page 5 of 9 |
|
|
0.55 (8.86%) 
